MINNEAPOLIS, Aug. 1, 2023 /PRNewswire/ — MEKanistic Therapeutics, a pioneering biotechnology company revolutionizing kinase inhibitors for cancer treatment, announced today that its investigational cancer clinical candidate MTX-531 has been approved for receiving continued development support from the National Cancer Institute’s (NCI) Experimental Therapeutics (NExT) Program. NCI is part of the…Read More
MEKanistic Therapeutics FirstinClass Cancer Clinical Candidate Approved to Receive Continued Development Support through the National Cancer Institutes Experimental Therapeutics NExT Program
